Subgroup analysis showed that patients with ZNF384 fusions had significantly higher RFS than B-other ALL with no ZNF384 fusions, patients with MLL rearrangement and TCF3-PBX1 fusions. This evidence concerns the gene ZNF384 and acute lymphoblastic leukemia.